Quantum BioPharma Ltd. has prevailed in its legal dispute with former CEO Dr. Raza Bokhari, with the Court of Appeal for Ontario fully dismissing a reconsideration motion filed by Bokhari. The court ruling reinforces the company's previous arbitration victory, which initially resulted in a cost award of approximately C$2.81 million plus interest.
The legal proceedings stem from Bokhari's termination for cause in 2021, following which he claimed wrongful dismissal. The additional court-awarded costs have elevated the total judgment amount to over C$3 million. Quantum BioPharma has proactively initiated U.S. collection proceedings, securing a favorable judgment from the U.S. District Court for the Eastern District of Pennsylvania.
Currently, Bokhari's appeal remains ongoing with a stay in place, supported by a supersedeas bond exceeding $2.8 million. The comprehensive legal resolution demonstrates Quantum BioPharma's commitment to protecting its corporate interests and maintaining robust governance standards.
